Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on share acquisition activities under the GSK ShareReward Plan.
Material Changes
On March 9, 2016, various Directors and PDMRs acquired GSK Ordinary Shares at a price of 1404.27 pence per share. The acquisitions were executed through the personal contribution and matching elements of the ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the share price of 1404.27 pence per Ordinary Share on March 9, 2016.
- Confirm the total number of shares acquired by each listed Director and PDMR under the ShareReward Plan.
- Review the specific terms of the GSK ShareReward Plan regarding personal contributions and company matching.